MYC and cancer: Recently, observations that the well‐known proto‐oncogene MYC controls pre‐mRNA splicing and that MYC‐driven cancers are susceptible to spliceosome inhibition have highlighted the use of pharmacological splicing modulators as promising anti‐cancer agents for MYC‐driven cancers (Hsu et al, 2015; Koh et al, 2015).